Diabetic Eye Disease Devices Market Size, Share and Growth Outlook, 2026

Diabetic Eye Disease Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Diabetic Eye Disease Devices Market size is forecast to increase from $1063.73 Million in 2026 to $1998.25 Million in 2034 at a CAGR of 8.2% between 2026 and 2034.

The Diabetic Eye Disease Devices market report provides detailed analysis and outlook of Diabetic Eye Disease Devices segments including By Product (Diagnostic & Screening Devices, Therapeutic & Surgical Devices ), By Target Disease Indication (Diabetic Retinopathy, Diabetic Macular Edema, Neovascular Glaucoma, Diabetes-Induced Cataracts), By Technology Platform (Traditional, AI-Enabled and Digital Software Integrated Systems), By End-User Facility (Specialized Eye Hospitals and Ophthalmology Clinics, General Hospitals and Tertiary Care Centers, Ambulatory Surgical Centers, Diagnostic Imaging Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Diabetic Eye Disease Devices Industry Overview

The diabetic eye disease devices industry is undergoing significant technological advancement as healthcare systems intensify efforts to prevent vision loss associated with diabetic retinopathy (DR) and diabetic macular edema (DME). Rising diabetes prevalence worldwide has increased the need for advanced ophthalmic devices, retinal imaging technologies, drug delivery systems, and artificial intelligence-based diagnostic platforms capable of supporting early detection and long-term disease management. Healthcare providers are increasingly adopting innovative diabetic retinopathy screening devices, retinal diagnostic systems, and sustained drug delivery technologies that improve patient outcomes while reducing treatment burden. The industry is evolving toward automated diagnostics, minimally invasive treatment approaches, and scalable screening infrastructures that can address growing patient populations while enhancing access to vision care services.

Sustained Drug Delivery Systems Transforming Diabetic Retinopathy Treatment

A major trend shaping the diabetic eye disease devices market is the development of long-acting ocular drug delivery platforms designed to reduce the frequency of intravitreal injections. Roche achieved a significant milestone with the U.S. Food and Drug Administration approval of Susvimo® (ranibizumab injection, 100 mg/mL) for the treatment of diabetic retinopathy. The technology combines a customized anti-vascular endothelial growth factor (anti-VEGF) formulation with a surgically implanted refillable port delivery system that continuously administers medication directly into the eye.
Unlike conventional diabetic retinopathy treatment approaches that require frequent injections, the Susvimo® system provides sustained therapeutic delivery for up to nine months before a routine office-based refill procedure is needed. This innovation represents a major advancement in diabetic eye disease management by reducing treatment frequency while maintaining continuous anti-VEGF therapy. The growing adoption of implantable ocular devices, sustained-release ophthalmic drug delivery systems, retinal disease treatment technologies, and long-acting anti-VEGF platforms is transforming the therapeutic landscape for diabetic retinopathy and diabetic macular edema management.

AI-Powered Retinal Screening Expanding Early Disease Detection

The diabetic eye disease devices industry is also experiencing rapid growth in artificial intelligence-enabled diagnostic technologies. Clinical evaluations conducted across multiple healthcare systems have highlighted widespread adoption of FDA-cleared autonomous AI screening platforms, including EyeArt® and IDx-DR, within primary care environments. These systems utilize non-mydriatic retinal imaging devices that capture high-resolution fundus photographs without requiring pupil dilation, making diabetic eye examinations faster and more accessible.
Advanced deep-learning algorithms analyze retinal images for clinically significant indicators such as microaneurysms, hemorrhages, and other early manifestations of diabetic retinopathy. The diagnostic process can be completed in less than five minutes, enabling healthcare providers to identify vision-threatening disease during routine diabetes management visits. The integration of AI retinal screening devices, automated diabetic retinopathy detection systems, non-mydriatic fundus cameras, and deep-learning diagnostic software is helping address screening gaps while supporting earlier intervention and improved visual outcomes.

National-Scale AI Screening Programs Driving Market Expansion

Large-scale deployment of AI-driven diabetic eye disease screening systems is emerging as another important growth driver within the diabetic eye disease devices market. Eyenuk, Inc. announced a landmark agreement that established the world's first national health system implementation of the EyeArt® AI Eye Screening System. The deployment integrates automated retinal grading algorithms directly into public healthcare databases, creating a standardized framework for diabetic eye disease screening across extensive municipal and multi-clinic healthcare networks.
By automating image interpretation and diagnostic classification, the system enables broader population-level screening for diabetic retinopathy and diabetic macular edema while reducing dependence on specialist review for initial assessments. This model improves accessibility, enhances screening consistency, and supports healthcare systems seeking scalable solutions for managing growing diabetic populations. The increasing adoption of AI ophthalmology devices, automated retinal diagnostics, population-based diabetic retinopathy screening technologies, and digital eye health platforms continues to accelerate innovation throughout the global diabetic eye disease devices industry, strengthening efforts to prevent avoidable diabetes-related vision loss.

Diabetic Eye Disease Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Diabetic Eye Disease Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Carl Zeiss Meditec AG, Topcon Corporation, Canon Medical Systems Corporation, Nidek Co., Ltd., Heidelberg Engineering GmbH, Optos plc (Nikon Corporation), Hologic, Inc., Bausch + Lomb Corporation, Euvision (Samsung Bioepis), AEYE Health (AI Diagnostics). The Diabetic Eye Disease Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Diabetic Eye Disease Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Diabetic Eye Disease Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Diabetic Eye Disease Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Diabetic Eye Disease Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Diabetic Eye Disease Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Diabetic Eye Disease Devices industry include- Carl Zeiss Meditec AG, Topcon Corporation, Canon Medical Systems Corporation, Nidek Co., Ltd., Heidelberg Engineering GmbH, Optos plc (Nikon Corporation), Hologic, Inc., Bausch + Lomb Corporation, Euvision (Samsung Bioepis), AEYE Health (AI Diagnostics). The Diabetic Eye Disease Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Diabetic Eye Disease Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Diabetic Eye Disease Devices market remains one of the strongest-performing segments in the country.
The US Diabetic Eye Disease Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Diabetic Eye Disease Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Diabetic Eye Disease Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Diabetic Eye Disease Devices markets

Canada's strong Diabetic Eye Disease Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Diabetic Eye Disease Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Diabetic Eye Disease Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Diabetic Eye Disease Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Diabetic Eye Disease Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Diabetic Eye Disease Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Diabetic Eye Disease Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Diabetic Eye Disease Devices sales through 2034

France Diabetic Eye Disease Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Diabetic Eye Disease Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Diabetic Eye Disease Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Diabetic Eye Disease Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Diabetic Eye Disease Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Diabetic Eye Disease Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Diabetic Eye Disease Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Diabetic Eye Disease Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Diabetic Eye Disease Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Diabetic Eye Disease Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Diabetic Eye Disease Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Diabetic Eye Disease Devices Market Segmentation

By Product
Diagnostic & Screening Devices
Therapeutic & Surgical Devices
By Target Disease Indication
Diabetic Retinopathy
Diabetic Macular Edema
Neovascular Glaucoma
Diabetes-Induced Cataracts
By Technology Platform
Traditional
AI-Enabled and Digital Software Integrated Systems
By End-User Facility
Specialized Eye Hospitals and Ophthalmology Clinics
General Hospitals and Tertiary Care Centers
Ambulatory Surgical Centers
Diagnostic Imaging Centers

Top Companies in Diabetic Eye Disease Devices Industry

Carl Zeiss Meditec AG
Topcon Corporation
Canon Medical Systems Corporation
Nidek Co., Ltd.
Heidelberg Engineering GmbH
Optos plc (Nikon Corporation)
Hologic, Inc.
Bausch + Lomb Corporation
Euvision (Samsung Bioepis)
AEYE Health (AI Diagnostics)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025